SUPPLEMENTAL MATERIAL

Gordon et al., https://10.1084/jem.20160758



Figure S1. **Representative flow cytometry gating strategy.** Gating strategy for a CMV-specific multimer (top) and Immudex negative control multimer (bottom) $CD8^+$ T cells in bone marrow from a male donor (donor 201, 21 yr of age).

Table S1. **Tissues analyzed from individual CMV seropositive donors**

Donor no.	Age	Blood	BM	Spleen	Lung LN	MLN	ILN	Lung	Colon	Tonsil	SG
	yr										
201	21	x	x	x	x	x	x	x	x	x	x
146	23	x	x		x		x	x	x		
207	23	x	x	x	x						
103	25	x	x	x	x	x		x	x		
227	26	x	x	x	x	x	x	x	x	x	x
204	30	x		x	x			x			
169	33	x			x	x	x	x	x	x	x
216	34	x	x		x	x	x	x	x		
174	35	x	x	x	x	x	x	x			
147	36	x	x	x	x	x	x	x			
195	37	x	x	x	x	x		x	x		
150	39	x	x	x	x	x	x	x	x		
156	40	x	x		x	x	x		x		
196	45	x	x		x	x	x	x	x		
172	49	x		x	x	x		x	x	x	x
217	49	x	x	x	x	x		x	x		
199	50	x		x	x	x	x	x	x		
194	53	x	x	x	x	x	x	x	x	x	x
208	54	x	x	x	x	x	x	x	x		
225	54	x	x	x	x			x			
220	64	x	x	x	x	x	x	x	x	x	x
226	66	x	x	x	x	x	x	x	x		x
190	69	x	x	x	x			x			
197	70				x	x	x	x			

X = tissues analyzed from that donor.

Table S2. **List of CMV-specific and control multimers used for analysis of human T cells**

HLA type	CMV epitope	Amino acid sequence	Source
A*0101	$pp50_{245-253}$	VTEHDTLLY	Proimmune, Immudex
A*0101	$pp65_{363-373}$	YSEHPTFTSQY	Proimmune
A*0201	$pp65_{495-503}$	NLVPMVATV	Proimmune, Immudex
A*0201	$IE1_{316-324}$	VLEETSVML	Proimmune
A*0201	$IE1_{81-89}$	VLAELVKQI	Proimmune
A*0301	$IE1_{184-192}$	KLGGALQAK	Proimmune, Immudex
A*2402	$pp65_{341-349}$	QYDPVAALF	Proimmune, Immudex
A*2402	$pp65_{113-121}$	VYALPLKML	Proimmune
A*6801	$pp65_{185-195}$	FVFPTKDVALR	National Institutes of Health Tetramer Core
B*0702	$pp65_{265-275}$	RPHERNGFTVL	Proimmune, Immudex
B*0702	$pp65_{417-426}$	TPRVTGGGAM	Proimmune, Immudex
B*3501	$pp65_{123-131}$	IPSINVHHY	Proimmune, Immudex
A*0201	NA	Negative control	Proimmune
General	NA	Negative control	Immudex

Table S3. **Characteristics of 72 organ donors used in Figs. 6 and 7**

Characteristic	CMV-seropositive donors	CMV-seronegative donors	P-value
	n = 44	*n* = 28	
Age in years (median [intraquartile range])	44 [32–54]	41 [25–54]	0.51
Male sex	66%	79%	0.30
Cause of death			
Cerebrovascular stroke	45%	46%	1.0
Head trauma	30%	22%	0.40
Anoxia	25%	28%	0.8
Other	0%	7%	0.15

Table S4. **List of fluorochrome-conjugated antibodies and flow cytometry reagents used in this study**

Antibody	Fluorochrome	Clone	Manufacturer
CD3	BV510	OKT3	BioLegend
CD3	BUV395	SK7	BD
CD4	APC-Cy7	OKT4	BioLegend
CD4	BV650	SK3	BD
CD8	BUV737	SK1	BD
CD19	BUV395	SJ25C1	BD
CD19	BUV496	SJ25C1	BD
CD45RA	BV605	HI100	BioLegend
CCR7	AF 488	G04H37	BioLegend
CD69	PerCp-Cy5.5	FN50	BioLegend
CD28	PE	CD28.2	eBioscience
CD57	PE/Dazzle594	HNK-1	BioLegend
CD107a	PE	H4A3	BioLegend
IFN-γ	AF700	B27	BD
Perforin	PE-CF594	δG9	BD
Viability	LIVE/DEAD Fixable Blue	NA	Life Technologies
Viability	DAPI	NA	BioLegend